Objective:Anlotinib hydrochloride is a multitarget tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor,fibroblast growth factor receptor,platelet-derived growth factor receptor,c-Kit,and...Objective:Anlotinib hydrochloride is a multitarget tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor,fibroblast growth factor receptor,platelet-derived growth factor receptor,c-Kit,and c-MET;therefore,it exhibits both antitumor and anti-angiogenetic activities.A phase III trial has shown that anlotinib improved progression-free survival(PFS)and overall survival(OS)in patients with advanced non-small cell lung cancer(NSCLC),who presented with progressive disease or intolerance after standard chemotherapy.This study aimed to analyze the characteristics of patients receiving anlotinib treatment to determine the dominant populations who are fit for the treatment.Methods:Data were collected from March 2015 to January 2017 from a randomized,double-blind,placebo-controlled,multicenter,phase III trial of anlotinib(ALTER0303).A total of 437 patients were enrolled and randomly allocated(2:1)to the anlotinib and placebo groups.Kaplan–Meier analysis and log-rank test were performed to compare PFS and OS.Cox proportional hazards model was adopted for multivariate prognostic analysis.Results:Multivariate analysis indicated that high post-therapeutic peripheral blood granulocyte/lymphocyte ratio and elevated alkaline phosphatase levels were independent risk factors for PFS.Meanwhile,elevated thyroid-stimulating hormone,blood glucose,and triglyceride levels;hypertension;and hand–foot syndrome were independent protective factors of PFS.High posttherapeutic peripheral blood granulocyte/lymphocyte ratio,an Eastern Cooperative Oncology Group(ECOG)score≥2,and the sum of the maximal target lesion length at baseline were independent risk factors of OS,and hypertriglyceridemia was an independent protective factor of OS.Conclusions:This study preliminarily explored the possible factors that affected PFS and OS after anlotinib treatment in patients with advanced refractory NSCLC,and the baseline characteristics of the therapeutically dominant populations were then identified.展开更多
铝电解槽节能的基本原理就是降低电解槽运行电压U和提高电流效率η。一般状态下获得较低电解槽电压的方法是通过电解槽母线优化配置获得小于5Gs的Bzave,但是研究发现,在采取通用母线配置方法获得小于5Gs的Bzave的条件下,电解槽的磁流体...铝电解槽节能的基本原理就是降低电解槽运行电压U和提高电流效率η。一般状态下获得较低电解槽电压的方法是通过电解槽母线优化配置获得小于5Gs的Bzave,但是研究发现,在采取通用母线配置方法获得小于5Gs的Bzave的条件下,电解槽的磁流体流速却较快,对炉帮的冲刷大而存在漏槽风险。在流速满足设计要求的条件下,Bzave值又难以满足小于5Gs的磁流体高稳定技术条件。本文深度剖析直流电耗达到12 000 k Wh/t.Al以下所采取的更进一步提高电解槽稳定性——抑制铝液层水平电流、曲面阴极降低流速、槽内衬保温匹配低电压等节能技术以及提高电流效率——氧化铝质量、电解质成分控制的关键技术问题。并对电解槽深度节能问题进行分析和探讨。展开更多
文摘Objective:Anlotinib hydrochloride is a multitarget tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor,fibroblast growth factor receptor,platelet-derived growth factor receptor,c-Kit,and c-MET;therefore,it exhibits both antitumor and anti-angiogenetic activities.A phase III trial has shown that anlotinib improved progression-free survival(PFS)and overall survival(OS)in patients with advanced non-small cell lung cancer(NSCLC),who presented with progressive disease or intolerance after standard chemotherapy.This study aimed to analyze the characteristics of patients receiving anlotinib treatment to determine the dominant populations who are fit for the treatment.Methods:Data were collected from March 2015 to January 2017 from a randomized,double-blind,placebo-controlled,multicenter,phase III trial of anlotinib(ALTER0303).A total of 437 patients were enrolled and randomly allocated(2:1)to the anlotinib and placebo groups.Kaplan–Meier analysis and log-rank test were performed to compare PFS and OS.Cox proportional hazards model was adopted for multivariate prognostic analysis.Results:Multivariate analysis indicated that high post-therapeutic peripheral blood granulocyte/lymphocyte ratio and elevated alkaline phosphatase levels were independent risk factors for PFS.Meanwhile,elevated thyroid-stimulating hormone,blood glucose,and triglyceride levels;hypertension;and hand–foot syndrome were independent protective factors of PFS.High posttherapeutic peripheral blood granulocyte/lymphocyte ratio,an Eastern Cooperative Oncology Group(ECOG)score≥2,and the sum of the maximal target lesion length at baseline were independent risk factors of OS,and hypertriglyceridemia was an independent protective factor of OS.Conclusions:This study preliminarily explored the possible factors that affected PFS and OS after anlotinib treatment in patients with advanced refractory NSCLC,and the baseline characteristics of the therapeutically dominant populations were then identified.
文摘铝电解槽节能的基本原理就是降低电解槽运行电压U和提高电流效率η。一般状态下获得较低电解槽电压的方法是通过电解槽母线优化配置获得小于5Gs的Bzave,但是研究发现,在采取通用母线配置方法获得小于5Gs的Bzave的条件下,电解槽的磁流体流速却较快,对炉帮的冲刷大而存在漏槽风险。在流速满足设计要求的条件下,Bzave值又难以满足小于5Gs的磁流体高稳定技术条件。本文深度剖析直流电耗达到12 000 k Wh/t.Al以下所采取的更进一步提高电解槽稳定性——抑制铝液层水平电流、曲面阴极降低流速、槽内衬保温匹配低电压等节能技术以及提高电流效率——氧化铝质量、电解质成分控制的关键技术问题。并对电解槽深度节能问题进行分析和探讨。
